Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Dec 16 2019
•
By
Brenda Sandburg
Sarepta did not publicly disclose that it made a formal dispute resolution request over Vyondys 53 complete response letter
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Compliance
More from Pink Sheet